Akebia Therapeutics/$AKBA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Ticker
$AKBA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
181
ISIN
US00972D1054
Website
AKBA Metrics
BasicAdvanced
$959M
-
-$0.21
0.88
-
Price and volume
Market cap
$959M
Beta
0.88
52-week high
$4.08
52-week low
$0.91
Average daily volume
6M
Financial strength
Current ratio
2.234
Quick ratio
1.917
Long term debt to equity
740.584
Total debt to equity
795.72
Interest coverage (TTM)
-0.78%
Profitability
EBITDA (TTM)
10.792
Gross margin (TTM)
83.23%
Net profit margin (TTM)
-24.51%
Operating margin (TTM)
-9.55%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Return on assets (TTM)
-4.26%
Return on equity (TTM)
3,385.36%
Valuation
Price to revenue (TTM)
4.315
Price to book
38.85
Price to tangible book (TTM)
-27.71
Price to free cash flow (TTM)
-22.883
Free cash flow yield (TTM)
-4.37%
Free cash flow per share (TTM)
-15.95%
Growth
Revenue change (TTM)
-1.24%
Earnings per share change (TTM)
-8.25%
3-year revenue growth (CAGR)
-5.77%
3-year earnings per share growth (CAGR)
-49.41%
10-year earnings per share growth (CAGR)
-19.94%
What the Analysts think about AKBA
Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.
Bulls say / Bears say
Leerink Partners initiated coverage of Akebia Therapeutics with an 'Outperform' rating and a price target suggesting a 216.07% upside, indicating strong analyst confidence in the company's growth potential. (nasdaq.com)
Akebia reported a net income of $6.11 million for Q1 2025, with earnings per share of $0.03, surpassing analyst expectations of a $0.04 loss, reflecting improved financial performance. (tradingview.com)
The company's anemia drug, Vafseo, is projected to generate $10-$11 million in net product revenue in Q1 2025, indicating promising early commercial performance. (investing.com)
Akebia reported a Q4 2024 loss of $22.8 million, or $0.10 per share, after a profit in the same period the previous year, indicating financial challenges. (seattlepi.com)
The company announced a public stock offering priced at $2 per share, a 29.6% discount to the last sale price, which led to a 26.1% drop in share value, reflecting potential dilution concerns. (tradingview.com)
Insider selling activity, including the CEO selling 144,250 shares and the SVP selling 50,506 shares, may signal a lack of confidence in the company's near-term prospects. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AKBA Financial Performance
Revenues and expenses
AKBA Earnings Performance
Company profitability
AKBA News
AllArticlesVideos
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
GlobeNewsWire·4 weeks ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akebia Therapeutics stock?
Akebia Therapeutics (AKBA) has a market cap of $959M as of June 30, 2025.
What is the P/E ratio for Akebia Therapeutics stock?
The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of June 30, 2025.
Does Akebia Therapeutics stock pay dividends?
No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Akebia Therapeutics dividend payment date?
Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akebia Therapeutics?
Akebia Therapeutics (AKBA) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.